Imagine a smart missile for cancer that first maps out exactly where the tumor is and then delivers a precise dose of medicine to kill it. Right now, this high-tech treatment is only available in a few elite hospitals. This effort is building a standardized 'recipe book' and delivery network so any hospital in Europe can provide these personalized treatments safely and quickly.
Advanced radiotheranostics are currently restricted to a few specialized centers due to a lack of standardized production and supply chains. This limits patient access to precision oncology and neurology treatments.
A European network of radiotheranostics centres, standardized radiochemical production methods, AI models for monitoring, and a clinical trial master protocol for Phase I/IIa trials.
If you are a manufacturer dealing with inefficient production of therapeutic ligands — this project developed standardized and scalable radiochemical methods that allow for faster, more consistent production of diagnostic and therapeutic tools.
If you are a clinic dealing with limited treatment capacity for solid tumors — this project developed a network of radiotheranostics centres and a clinical trial master protocol that accelerates the time to treat patients.
If you are a software company dealing with imprecise therapy monitoring — this project developed AI models and PET/SPECT imaging protocols that optimize patient outcomes through better quantitation.
Based on available project data, specific pricing or implementation costs are not provided.
The project focuses on creating standardized, scalable radiochemical methods for labelling and production, as well as establishing sustainable supply and production networks across public and private sectors.
Based on available project data, the specific IP and licensing terms are not mentioned, though the project involves 16 industry partners.
The project has a dedicated work package (WP2) specifically focused on Regulatory aspects to ensure the developed tools can be implemented in clinical settings.
The project runs from 2024-10-01 to 2029-09-30, indicating a 5-year development and implementation cycle.
The consortium is heavily weighted toward commercial application, with a 53% industry ratio comprising 16 partners, including 9 SMEs. This strong industrial presence, combined with 6 universities and 4 research institutes across 15 countries, suggests a high likelihood of technology transfer and a focus on scalable, market-viable production methods rather than purely academic research.
Contact UNIVERSITA CATTOLICA DEL SACRO CUORE in Italy
Contact us to identify specific radiopharmaceutical partners within the Thera4Care network.
